Navigation Links
Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference
Date:4/9/2015

SAN DIEGO, April 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015, at 12:50 p.m. Eastern Time (9:50 a.m. Pacific Time), at the Westin Grand Central Hotel in New York City.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ® (lorcaserin HCl) is Arena's first internally discovered drug approved for marketing. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; the risk that Arena's revenues are based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's and third parties' intellectual property rights; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersScott A. Rieger

David Schull Senior Director, Investor Relations

President srieger@arenapharm.com  

david.schull@russopartnersllc.com 858.453.7200, ext. 1347

858.717.2310 www.arenapharm.com  


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Government of Canada and Heart and Stroke Foundation deliver on commitment to install AEDs in recreational hockey arenas
2. Stethoscopes - Global Strategic Business Report 2015-2020: 3M - An Ace in the Global Stethoscopes Arena
3. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Monday, March 2
4. Arena Pharmaceuticals to Present at the 2015 RBC Capital Markets Healthcare Conference
5. Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
7. Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
8. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
9. Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
10. Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
11. Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... (PRWEB) , ... January 07, 2020 , ... ... first calibration-free blood pressure (BP) sensor system for integration in hearables and wearables. ... device and consumer electronics manufacturers for inclusion in their products. Embedded in an ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST, https://www.fdanews.com/chinanpma , China ... It is the only market with a 20 percent annual growth rate year ...
(Date:1/3/2020)... ... 2020 , ... In Partnership with the Smiles for Everyone Foundation , ... its Burleson, TX office on February 8th. , Dental services provided include same-day procedures ... extractions . For more information, please visit the Monarch Dental website . ...
Breaking Medicine Technology:
(Date:1/12/2020)... ... January 11, 2020 , ... The co-founder and CEO of ... with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, ... technology company investors and advisers at the San Francisco office of international law ...
(Date:1/10/2020)... ... January 10, 2020 , ... Sigma Theta Tau International Honor ... of the Year Awards. These awards are regarded as one of the most important ... the AJN Book of the Year competition has recognized Sigma for the last 11 ...
(Date:1/10/2020)... ... January 10, 2020 , ... ... of autoimmune conditions, HMP, a leading healthcare event and education company, today announced ... patient care. , The Autoimmune Learning Network serves as a robust digital hub ...
(Date:1/10/2020)... , ... January 10, 2020 , ... ... in Portland, Oregon, provides a friendly, non-intimidating environment for all women. In search ... Habits to its current and prospective members. , For nearly 30 years, ...
(Date:1/8/2020)... ... 08, 2020 , ... Myant Inc., leaders in Textile Computing™, ... by the Myant Platform at CES 2020, happening January 7-10, in Las ... the Myant Platform will be aware of the worker’s current physical and psychological ...
Breaking Medicine News(10 mins):